Business Context and Reporting Period
This Form 8-K filing by Ultragenyx Pharmaceutical Inc. reports a material definitive agreement entered into on January 23, 2018. The document details an underwritten public offering of common stock that closed on January 26, 2018.
Key Financial Metrics
- Shares Sold: 4,385,965 shares initially, plus 657,895 additional shares via full exercise of the underwriters' option, totaling 5,043,860 shares.
- Offering Price: $57.00 per share.
- Price to Company: $53.72 per share (after underwriting discounts).
- Net Proceeds: Approximately $270.3 million after deducting discounts, commissions, and estimated offering expenses.
- Underwriters: J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Goldman Sachs & Co. LLC, and Cowen and Company, LLC.
Material Changes
The filing does not provide comparative financial data (revenue, profit, or margins) as it is a current report regarding a capital raise rather than a periodic financial statement. The primary material change is the significant increase in cash liquidity resulting from the $270.3 million in net proceeds.
Outlook, Risks, and Contingencies
The Company agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933 or to contribute to payments required by the Underwriters. The offering was conducted under an automatically effective shelf registration statement (Form S-3, No. 333-201838). No specific forward-looking guidance or operational risks were detailed in this specific filing text beyond the standard indemnification obligations.
Investor Verification Checklist
- Verify the final closing date of the offering (January 26, 2018) and the full exercise of the 30-day option.
- Confirm the exact net proceeds of $270.3 million against the total shares sold (5,043,860) and the price per share ($53.72).
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific indemnification terms and lock-up provisions.
- Check subsequent filings to determine the intended use of the raised capital.